» Articles » PMID: 27401785

Expression, Purification and Biological Activity Assessment of Romiplostim Biosimilar Peptibody

Overview
Journal Daru
Specialty Pharmacology
Date 2016 Jul 13
PMID 27401785
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Romiplostim is a peptibody analogue of thrombopoietin (TPO) which regulates platelet production. This molecule consists of two main parts: Peptide sequences which like wild type TPO, mimics stimulation of TPO receptor and IgG1Fc, (Peptide + Antibody = Peptibody). This drug is used in treatment of chronic Immune Thrombocytopenic Purpura (ITP).

Methods: In this project E. coli bacteria were transformed by a construct harboring peptibody fusion gene. This construct consisted of two repeated peptide sequences which have fused to Carboxyl group of IgG1Fc. Designed construct in E. coli host resulted in protein expression in cytoplasm as inclusion body. The inclusion bodies were separated, washed and after denaturation and solubilization, in the last stage the desired peptibodies were refolded and purified. The resulting peptibodies were characterized by SDS-PAGE and Western immunoblotting. The bioactivity were assessed in vivo using subcutaneous injection in mice.

Results: Results showed accurate molecules were produced and purified. Also, in vivo experiment showed significant increment (more than two fold) of platelets compared to control group.

Conclusion: In this study laboratory scale production of recombinant romiplostim showed proper in-vivo bioactivity. This new approach in expression and purification of this recently introduced thrombopoietin receptor agonist drug may be followed by scale up of its production to response the chronic ITP patient's demand.

Citing Articles

Targeted cancer treatment using a novel EGFR-specific Fc-fusion peptide based on GE11 peptide.

Hallaji M, Allahyari M, Teimoori-Toolabi L, Yasami-Khiabani S, Golkar M, Fard-Esfahani P Sci Rep. 2025; 15(1):5107.

PMID: 39934226 PMC: 11814073. DOI: 10.1038/s41598-025-89143-5.


Protein Expression and Purification of Romiplostim and Analysis of Its Secretory Production Using an Investigated Signal Peptide in .

Hashemzaei M, Negahdaripour M, Heidari R, Ghoshoon M Rep Biochem Mol Biol. 2023; 12(1):27-35.

PMID: 37724139 PMC: 10505470. DOI: 10.52547/rbmb.12.1.27.


Quality by Design in Downstream Process Development of Romiplostim.

Pouri S, Torkashvand F, Aliabadi H, Fard-Esfahani P, Golkar M, Vaziri B Iran Biomed J. 2022; 26(6):414-25.

PMID: 36439274 PMC: 9841220. DOI: 10.52547/ibj.3790.


Comparison of E. coli based self-inducible expression systems containing different human heat shock proteins.

Shariati F, Keramati M, Valizadeh V, Cohan R, Norouzian D Sci Rep. 2021; 11(1):4576.

PMID: 33633341 PMC: 7907268. DOI: 10.1038/s41598-021-84188-8.


FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1.

Jendryczko K, Chudzian J, Skinder N, Opalinski L, Rzeszotko J, Wiedlocha A Cancers (Basel). 2020; 12(10).

PMID: 33076489 PMC: 7602595. DOI: 10.3390/cancers12102992.


References
1.
Stasi R, Bosworth J, Rhodes E, Shannon M, Willis F, Gordon-Smith E . Thrombopoietic agents. Blood Rev. 2010; 24(4-5):179-90. DOI: 10.1016/j.blre.2010.04.002. View

2.
Frederiksen H, Schmidt K . The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999; 94(3):909-13. View

3.
Kuter D . New thrombopoietic growth factors. Blood. 2007; 109(11):4607-16. PMC: 1885525. DOI: 10.1182/blood-2006-10-019315. View

4.
Li J, Xia Y, Kuter D . Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999; 106(2):345-56. DOI: 10.1046/j.1365-2141.1999.01571.x. View

5.
Kaushansky K . The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005; 115(12):3339-47. PMC: 1297257. DOI: 10.1172/JCI26674. View